Navigation Links
New route to identify drugs that can fight bacterial infections
Date:7/28/2014

About 100 drugs already approved by the U.S. Food and Drug Administration (FDA) for other purposes can also prevent the growth of certain bacterial pathogens inside human cells, including those that cause Legionnaires' disease, brucellosis, and Mediterranean spotted fever. The findings, published in mBio, the online open-access journal of the American Society for Microbiology, demonstrate a new way of identifying non-antibiotic drugs that could one day help curb bacterial infections.

A handful of drugs on the list inhibit the growth of at least three of the four bacterial organisms tested. Those drugs include familiar compounds like loperamide, an antidiarrheal medication sold under the brand name Imodium and clemastine, an allergy medicine sold as Tavist, as well as drugs used to treat high blood pressure and angina.

Howard Shuman, professor of microbiology at the University of Chicago and a senior author on the study cautions that this study only looked at infection in the laboratory dish and therefore whether the drugs would effectively treat infections in humans is not known. The work, he says, is a good first step showing this method can identify FDA-approved drugs that might potentially act alongside traditional antibiotics.

"Antibiotic therapy is becoming more difficult to achieve, so looking for alternatives is always a good thing to do," Shuman says.

Shuman and his colleagues thought that certain types of bacteriathose that infect human cells and then replicate inside those cellsmight be vulnerable to other drug approaches.

"Intracellular bacteria resemble viruses in that they need host cell functions to complete their life cycle," says Shuman. So the researchers screened drugs to look for compounds that interfered with those cellular processes. They chose a panel of 640 FDA-approved drugs that have known safety and side effect profiles.

The researchers measured each drug's ability to disrupt the intracellular growth of four bacterial strains: Coxiella burnetii (which causes Q fever), Legionella pneumophila (Legionnaires' disease), Brucella abortus (brucellosis), and Rickettsia conorii (Mediterranean spotted fever). Although none of these organisms have become problem infections in the U.S. due to antibiotic resistance, brucellosis and Q fever can both cause chronic and ultimately fatal disease in about 5% of those infected.

The team screened each drug for its ability to reduce intracellular bacterial growth by 80% or more inside human THP-1 macrophage-like immune cells. They eliminated drugs from the list that simply killed off the human host cells or that were known antibiotic or antiviral drugs and identified 101 drugs that presumably disrupt key cellular functions in the host cells.

Shuman's lab group did the experiments on C. brunetii and L. pneumophila, while Sean Crosson's group at University of Chicago carried out the B. abortus work, and Juan Martinez's group, now at Louisiana State University in Baton Rouge, performed the R. conorii studies. The work, which was done at the Howard T. Ricketts Laboratory, a biocontainment laboratory operated by the University of Chicago in Lemont, Illinois, shows that known drugs that interfere with host cell properties can stall intracellular bacterial infections.

"There are emerging infections of all sortsbacteria, viruses, parasites. Working up a new therapy for such things take time," says Shuman. "If we have drugs X, Y, or Z to interfere with host cell functions to slow or impede an infection, then we can have something already on hand to attack it."


'/>"/>

Contact: Jim Sliwa
jsliwa@asmusa.org
202-942-9297
American Society for Microbiology
Source:Eurekalert

Related biology news :

1. How bumblebees find efficient routes without a GPS
2. A better route to xylan
3. Novel combination therapy shuts down escape route, killing glioblastoma tumor cells
4. Transmission routes of spreading protein particles
5. A fly mutation suggests a new route for tackling ALS
6. Antibiotics: Change route of delivery to mitigate resistance
7. A route for steeper, cheaper, and deeper roots
8. UT Arlington nanoparticles could provide easier route for cell therapy
9. Study provides insights into birds migration routes
10. Beyond the microscope: Identifying specific cancers using molecular analysis
11. Researchers identify new regulator in allergic diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2016)... 2016 http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ... the  "Global Behavioral Biometric Market 2016-2020" ... http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the ... Market 2016-2020"  report to their offering. ... http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the addition ...
(Date:1/20/2016)... SAN JOSE, Calif. , Jan. 20, 2016 ... leading developer of human interface solutions, today announced ... touch controller solution for wearables and small screen ... appliances such as printers. Supporting round and rectangular ... the S1423 offers excellent performance with moisture on ...
(Date:1/11/2016)... Jan. 11, 2016 Synaptics Incorporated (NASDAQ: ... today announced that its ClearPad ® TouchView ™ ... won two separate categories in the 8 th ... Best Technology Breakthrough. The Synaptics ® TDDI solution ... supply chain, thinner devices, brighter displays and borderless designs. ...
Breaking Biology News(10 mins):
(Date:2/3/2016)... Feb. 3, 2016  With the growing need ... that is underway, therapies such as monoclonal antibodies, ... whole host of indications are in high demand. ... the development and production of these therapeutics. However, ... and high costs, novel approaches and novel expression ...
(Date:2/3/2016)... Feb. 3, 2016 New Jersey Health Foundation ... $1 million for researchers in New ... research that demonstrates exciting potential.   ... for the New Jersey Health Foundation Research Grant ... these educational institutions— Princeton University, Rutgers University, Rowan ...
(Date:2/3/2016)... ... February 03, 2016 , ... ... Unix visualization solutions today announced the addition of a powerful “Session Preview” feature ... see the current state of the remote Linux desktop or other applications (sessions) ...
(Date:2/3/2016)... Calif. , Feb. 3, 2016  Today, Symphony ... of AlphaImpactRx , a leading provider of primary ... companies to IMS Health , a global information ... complementary offerings, capabilities and technologies will be integrated into ... growing global primary market research capabilities. ...
Breaking Biology Technology: